Depot characteristics and biodistribution of interleukin-2 liposomes: Importance of route of administration

P. M. Anderson, Emmanuel Katsanis, S. F. Sencer, D. Hasz, A. C. Ochoa, B. Bostrom

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Due to rapid clearance of interleukin-2 (IL-2), it has had limited effective use as an in vivo immunostimulant. Current experimental and clinical protocols generally must utilize large doses, multiple injections, or continuous infusions of IL-2 in order to achieve significant immunostimulation, often at the expense of systemic toxicity. Therefore, the pharmacodynamics of IL-2 liposomes were investigated. IL-2 liposome incorporation efficiency was 80.4% (SD 5.5); vesicle diameter was 1.65 μm (SD 0.09) as determined by fluorescence-activated cell sorting (FACS). Both formulation (free cytokine vs. IL-2 liposomes) and route of administration were important variables in determination of the biodistribution and pharmacokinetic characteristics of IL-2. When free [125I]IL-2 was given i.v. to mice, only 6.5% was in the blood and 3% in liver and spleen 2 h after injection; on the other hand, at 2 h > 70% of i.v. [125I]IL-2 liposomes were detected in the blood, liver, spleen, and lungs. Mean i.v. elimination t( 1/2 ) from the blood of rats given 20 x 106 U/kg free cytokine or IL-2 liposomes was 41 versus 102 min, respectively, as measured by bioassay and 59 and 119 min as measured by enzyme immunoassay (EIA). After i.v. administration, the estimated V(d) of IL-2 liposomes was 13-fold smaller than the free cytokine. Intrathoracic (i.tx.), i.p., and s.c. administration of [125I]IL-2 to mice also demonstrated significant depot effects when IL-2 was incorporated into liposomes. These data suggest IL-2 liposomes may provide in vivo immunostimulation superior to the free cytokine due to biodistribution and depot characteristics.

Original languageEnglish (US)
Pages (from-to)19-31
Number of pages13
JournalJournal of Immunotherapy
Volume12
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Liposomes
Interleukin-2
Cytokines
Immunization
Spleen
Immunologic Adjuvants
Injections
Liver
Clinical Protocols
Immunoenzyme Techniques
Biological Assay
Flow Cytometry
Pharmacokinetics
Lung

Keywords

  • Cytokine
  • Interleukin-2
  • Liposomes
  • Pharmacokinetics

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Depot characteristics and biodistribution of interleukin-2 liposomes : Importance of route of administration. / Anderson, P. M.; Katsanis, Emmanuel; Sencer, S. F.; Hasz, D.; Ochoa, A. C.; Bostrom, B.

In: Journal of Immunotherapy, Vol. 12, No. 1, 1992, p. 19-31.

Research output: Contribution to journalArticle

Anderson, PM, Katsanis, E, Sencer, SF, Hasz, D, Ochoa, AC & Bostrom, B 1992, 'Depot characteristics and biodistribution of interleukin-2 liposomes: Importance of route of administration', Journal of Immunotherapy, vol. 12, no. 1, pp. 19-31.
Anderson, P. M. ; Katsanis, Emmanuel ; Sencer, S. F. ; Hasz, D. ; Ochoa, A. C. ; Bostrom, B. / Depot characteristics and biodistribution of interleukin-2 liposomes : Importance of route of administration. In: Journal of Immunotherapy. 1992 ; Vol. 12, No. 1. pp. 19-31.
@article{f82d3d3dfbea4550bfd00cab25ea2df5,
title = "Depot characteristics and biodistribution of interleukin-2 liposomes: Importance of route of administration",
abstract = "Due to rapid clearance of interleukin-2 (IL-2), it has had limited effective use as an in vivo immunostimulant. Current experimental and clinical protocols generally must utilize large doses, multiple injections, or continuous infusions of IL-2 in order to achieve significant immunostimulation, often at the expense of systemic toxicity. Therefore, the pharmacodynamics of IL-2 liposomes were investigated. IL-2 liposome incorporation efficiency was 80.4{\%} (SD 5.5); vesicle diameter was 1.65 μm (SD 0.09) as determined by fluorescence-activated cell sorting (FACS). Both formulation (free cytokine vs. IL-2 liposomes) and route of administration were important variables in determination of the biodistribution and pharmacokinetic characteristics of IL-2. When free [125I]IL-2 was given i.v. to mice, only 6.5{\%} was in the blood and 3{\%} in liver and spleen 2 h after injection; on the other hand, at 2 h > 70{\%} of i.v. [125I]IL-2 liposomes were detected in the blood, liver, spleen, and lungs. Mean i.v. elimination t( 1/2 ) from the blood of rats given 20 x 106 U/kg free cytokine or IL-2 liposomes was 41 versus 102 min, respectively, as measured by bioassay and 59 and 119 min as measured by enzyme immunoassay (EIA). After i.v. administration, the estimated V(d) of IL-2 liposomes was 13-fold smaller than the free cytokine. Intrathoracic (i.tx.), i.p., and s.c. administration of [125I]IL-2 to mice also demonstrated significant depot effects when IL-2 was incorporated into liposomes. These data suggest IL-2 liposomes may provide in vivo immunostimulation superior to the free cytokine due to biodistribution and depot characteristics.",
keywords = "Cytokine, Interleukin-2, Liposomes, Pharmacokinetics",
author = "Anderson, {P. M.} and Emmanuel Katsanis and Sencer, {S. F.} and D. Hasz and Ochoa, {A. C.} and B. Bostrom",
year = "1992",
language = "English (US)",
volume = "12",
pages = "19--31",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Depot characteristics and biodistribution of interleukin-2 liposomes

T2 - Importance of route of administration

AU - Anderson, P. M.

AU - Katsanis, Emmanuel

AU - Sencer, S. F.

AU - Hasz, D.

AU - Ochoa, A. C.

AU - Bostrom, B.

PY - 1992

Y1 - 1992

N2 - Due to rapid clearance of interleukin-2 (IL-2), it has had limited effective use as an in vivo immunostimulant. Current experimental and clinical protocols generally must utilize large doses, multiple injections, or continuous infusions of IL-2 in order to achieve significant immunostimulation, often at the expense of systemic toxicity. Therefore, the pharmacodynamics of IL-2 liposomes were investigated. IL-2 liposome incorporation efficiency was 80.4% (SD 5.5); vesicle diameter was 1.65 μm (SD 0.09) as determined by fluorescence-activated cell sorting (FACS). Both formulation (free cytokine vs. IL-2 liposomes) and route of administration were important variables in determination of the biodistribution and pharmacokinetic characteristics of IL-2. When free [125I]IL-2 was given i.v. to mice, only 6.5% was in the blood and 3% in liver and spleen 2 h after injection; on the other hand, at 2 h > 70% of i.v. [125I]IL-2 liposomes were detected in the blood, liver, spleen, and lungs. Mean i.v. elimination t( 1/2 ) from the blood of rats given 20 x 106 U/kg free cytokine or IL-2 liposomes was 41 versus 102 min, respectively, as measured by bioassay and 59 and 119 min as measured by enzyme immunoassay (EIA). After i.v. administration, the estimated V(d) of IL-2 liposomes was 13-fold smaller than the free cytokine. Intrathoracic (i.tx.), i.p., and s.c. administration of [125I]IL-2 to mice also demonstrated significant depot effects when IL-2 was incorporated into liposomes. These data suggest IL-2 liposomes may provide in vivo immunostimulation superior to the free cytokine due to biodistribution and depot characteristics.

AB - Due to rapid clearance of interleukin-2 (IL-2), it has had limited effective use as an in vivo immunostimulant. Current experimental and clinical protocols generally must utilize large doses, multiple injections, or continuous infusions of IL-2 in order to achieve significant immunostimulation, often at the expense of systemic toxicity. Therefore, the pharmacodynamics of IL-2 liposomes were investigated. IL-2 liposome incorporation efficiency was 80.4% (SD 5.5); vesicle diameter was 1.65 μm (SD 0.09) as determined by fluorescence-activated cell sorting (FACS). Both formulation (free cytokine vs. IL-2 liposomes) and route of administration were important variables in determination of the biodistribution and pharmacokinetic characteristics of IL-2. When free [125I]IL-2 was given i.v. to mice, only 6.5% was in the blood and 3% in liver and spleen 2 h after injection; on the other hand, at 2 h > 70% of i.v. [125I]IL-2 liposomes were detected in the blood, liver, spleen, and lungs. Mean i.v. elimination t( 1/2 ) from the blood of rats given 20 x 106 U/kg free cytokine or IL-2 liposomes was 41 versus 102 min, respectively, as measured by bioassay and 59 and 119 min as measured by enzyme immunoassay (EIA). After i.v. administration, the estimated V(d) of IL-2 liposomes was 13-fold smaller than the free cytokine. Intrathoracic (i.tx.), i.p., and s.c. administration of [125I]IL-2 to mice also demonstrated significant depot effects when IL-2 was incorporated into liposomes. These data suggest IL-2 liposomes may provide in vivo immunostimulation superior to the free cytokine due to biodistribution and depot characteristics.

KW - Cytokine

KW - Interleukin-2

KW - Liposomes

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0026664243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026664243&partnerID=8YFLogxK

M3 - Article

C2 - 1637781

AN - SCOPUS:0026664243

VL - 12

SP - 19

EP - 31

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -